Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 630

Sort by

Sort Order Select

Journal Articles

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Mehdi Hamadani, John Radford, Carmelo Carlo-Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay M. Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl

Blood (2021) 137 (19): 2634–2645.

https://doi.org/10.1182/blood.2020007512

Published: 2021

Includes: Supplemental data

Journal Articles

Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis

Isabella McCary, BS, Christine Guelcher, PPCNP-BC, Jan Kuhn, BA, BSN, MSN, Regina Butler, RN-BC, Michael F. Guerrera, MD, Gita Massey, Leslie J. Raffini, MD

Blood (2019) 134 (Supplement_1): 2396.

https://doi.org/10.1182/blood-2019-126944

Published: 2019

Journal Articles

Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 765.

https://doi.org/10.1182/blood-2019-125769

Published: 2019

Journal Articles

Clinical Outcome of an Multicentre, Randomized, Phase II Clinical Trial for Patients with Extranodal NK/T Cell Lymphoma Treated By P-Gemox or Aspametdex

Hui-qiang Huang, Gao Yan, Hang Su, Yunhong Huang, Yuhuan Gao, Wang Xiaoxiao, Bai Bing, Yujing Zhang, Liping Su, Xiaoxia Chu, Wenyu Li, MD PhD, Junyi Zhang, Qiaohua Zhang, MD, Liansheng Zhang, Xiaohua Hu, Liqun Zou, Zhiming Li, Wenqi Jiang

Blood (2019) 134 (Supplement_1): 1569.

https://doi.org/10.1182/blood-2019-123478

Published: 2019

Journal Articles

CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma

Peter Herhaus, MD, Jana Lipkova, Felicitas Lammer, MD, Julia Slotta-Huspenina, MD, Benedikt Wiestler, MD, Tibor Vag, MD, Stefan Habringer, MD, Igor Yakushev, MD, Constantin Lapa, MD, Tobias Pukrop, MD, Dirk Hellwig, MD, Andreas Buck, MD, Martina Deckert, MD, Hans-Jürgen Wester, PhD, Florian Bassermann, MD PhD, Wolfgang Weber, MD, Markus Schwaiger, MD, Björn Menze, PhD, Ulrich Keller, MD

Blood (2019) 134 (Supplement_1): 2900.

https://doi.org/10.1182/blood-2019-126024

Published: 2019

Journal Articles

Incidence of Delayed Seromas and Related Risk of Bia-ALCL in a Cohort of 3521 Breast Cancer Women with Textured Implants Prospectively Followed Long Term

Paola Ghione, MD, Peter Cordeiro, MD, Venkatraman Seshan, PhD, Natasha Galasso, Nivetha Ganesan, MPH, Qunying Hu, Ahmet Dogan, MD PhD, Steven M. Horwitz, MD

Blood (2019) 134 (Supplement_1): 2842.

https://doi.org/10.1182/blood-2019-122572

Published: 2019

Journal Articles

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO)

Anna Vanazzi, MD, Safaa Ramadan, PhD MD, Francesca De Lorenzi, MD, Paola Arena, MD, Enrico Derenzini, MD PhD, Mario Rietjens, Anna Rotili, MD, Antuono Latronico, MD, Laura Travaini, MD, Emanuela Omodeo Sale', Daniela Malengo, Marianna Gerardi, Stefano Fiori, MD, Valentina Tabanelli, MD, Stefano A Pileri, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 5283.

https://doi.org/10.1182/blood-2019-125239

Published: 2019

Journal Articles

Coexistence of a Huge Venous Thromboembolism and Bleeding Tendency in Cytokine Release Syndrome during CAR-T Therapy

Haiyan Liu, MD, Ye Yang, PhD, Hongming Huang, MD

Blood (2019) 134 (Supplement_1): 5590.

https://doi.org/10.1182/blood-2019-129389

Published: 2019

Journal Articles

Bispecific T-Cell Engager (BiTE) Antibody Based Immunotherapy for Treatment of Relapsed Refractory Multiple Myeloma (RRMM): A Systematic Review of Preclinical and Clinical Trials

Zunairah Shah, MBBS, Mustafa Nadeem Malik, MD, Syeda Sabeeka Batool, MBBS, MD, Sravanthi Kotapati, MBBS, Aisha Akhtar, MBBS, Owais ur Rehman, MBBS, Marium Ghani, MBBS, Maryam Sadiq, MBBS, Arshia Akbar, MD, Aqsa Ashraf, MBBS, Arafat Ali Ali Farooqui, MD, Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Hafiz Muhammad Fazeel, MBBS, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5567.

https://doi.org/10.1182/blood-2019-129652

Published: 2019

Journal Articles

A Case Report of the Benefit of Cannabidiol (Cannabidiol (CBD)-Predominant Medical Cannabis Preparation) in the Management of Refractory Skin Graft Vs Host Disease (GVHD)

Tsiporah B. Shore, MD, Jessy B. Ryan, ANP, Michael B. Samuel, MD

Blood (2019) 134 (Supplement_1): 5687.

https://doi.org/10.1182/blood-2019-122715

Published: 2019

Journal Articles

Diagnostic Delay and Characterization of the Clinical Prodrome in AL Amyloidosis: Data from 1,313 US Commercially Insured Patients between 2006-2018

Laura L Hester, PhD MSc, Dina M Gifkins, PhD MPH, Kevin M Bellew, MS, MA, Jessica Vermeulen, MD PhD, Jordan M Schecter, MD, Frank J DeFalco, Brendan M Weiss, MD

Blood (2019) 134 (Supplement_1): 5517.

https://doi.org/10.1182/blood-2019-124250

Published: 2019

Journal Articles

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Blood (2019) 134 (Supplement_1): 4296.

https://doi.org/10.1182/blood-2019-128470

Published: 2019

Journal Articles

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study

Raajit K. Rampal, MD PhD, Srdan Verstovsek, MD PhD, Sean M. Devlin, PhD, Amber C. King, PharmD, BCOP, Eytan M. Stein, MD, Naveen Pemmaraju, MD, Michael J. Mauro, MD, Tapan M. Kadia, MD, Guillermo Montalban-Bravo, MD, Kelsey Alvarez, RN, Nicole Ard, Tawni Goodman, Bria Taylor, Prithviraj Bose, MD

Blood (2019) 134 (Supplement_1): 4163.

https://doi.org/10.1182/blood-2019-127661

Published: 2019

Journal Articles

Initial Safety and Efficacy of Dose-Escalating HDACs Inhibitor Chidamide with VRD (Chi-VRD) Treatment for Newly-Diagnosed High-Risk Transplant Eligible Multiple Myeloma Patients

Jingjing Shang, Weiqin Yao, Lingzhi Yan, Xiaolan Shi, Ruju Wang, Shuang Yan, Yong Liu, Depei Wu, MD PhD, Fu Cheng Cheng, MD PhD

Blood (2019) 134 (Supplement_1): 1855.

https://doi.org/10.1182/blood-2019-129434

Published: 2019

Journal Articles

A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome

Blood (2019) 134 (Supplement_1): 1846.

https://doi.org/10.1182/blood-2019-127366

Published: 2019

Journal Articles

Upfront Ixazomib Plus Dexamethasone Induce Promptly Hematological Response in Patients with Light-Chain Amyloidosis

Zheng Wei, MD, Yian Zhang, Jing Li, MD, Peng Liu, MD

Blood (2019) 134 (Supplement_1): 1908.

https://doi.org/10.1182/blood-2019-127023

Published: 2019

Journal Articles

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Bjørn T. Gjertsen, MD PhD, Andreas Hochhaus, MD, Gianantonio Rosti, MD, Justin M. Watts, MD, Guillermo Ortí, Philipp le Coutre, MD, Eric Leip, PhD, Andrea Viqueira, MD, Jorge E. Cortes, MD, Frank Giles, MD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1639.

https://doi.org/10.1182/blood-2019-121815

Published: 2019

Journal Articles

Clinical Features and Outcomes of Unifocal Adult Langerhans Cell Histiocytosis

Marie Hu, MD, Gaurav Goyal, MBBS, Jason Young, MD, Karen Rech, MD, N. Nora Bennani, MD, Mithun Vinod Shah, MD PhD, Robert Vassallo, MD, Jay H Ryu, MD, Ronald S. Go, MD

Blood (2019) 134 (Supplement_1): 1667.

https://doi.org/10.1182/blood-2019-132104

Published: 2019

Journal Articles

Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel

Ajeet Gajra, MD FACP, Marjorie E Zettler, PhD MPH, Eli G Phillips Jr., PharmD, JD, Andrew J Klink, PhD MPH, Jonathan K. Kish, PhD MPH, Sonam Mehta, Bruce Feinberg, DO

Blood (2019) 134 (Supplement_1): 1952.

https://doi.org/10.1182/blood-2019-129593

Published: 2019

Journal Articles

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, Milos D. Miljkovic, MDMSc, Jagan R. Muppidi, MD PhD, Craig A. Portell, MD, Rafic Farah, MD, Seung Tae Lee, MD PhD, Anna Marie Juanitez, RN, Lydia L. Chou, CRNP, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis Staudt, MD, Mark Roschewski, MD, Wyndham Wilson, MD

Blood (2019) 134 (Supplement_1): 2867.

https://doi.org/10.1182/blood-2019-125990

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis

Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Clinical Outcome of an Multicentre, Randomized, Phase II Clinical Trial for Patients with Extranodal NK/T Cell Lymphoma Treated By P-Gemox or Aspametdex

CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma

Incidence of Delayed Seromas and Related Risk of Bia-ALCL in a Cohort of 3521 Breast Cancer Women with Textured Implants Prospectively Followed Long Term

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO)

Coexistence of a Huge Venous Thromboembolism and Bleeding Tendency in Cytokine Release Syndrome during CAR-T Therapy

Bispecific T-Cell Engager (BiTE) Antibody Based Immunotherapy for Treatment of Relapsed Refractory Multiple Myeloma (RRMM): A Systematic Review of Preclinical and Clinical Trials

A Case Report of the Benefit of Cannabidiol (Cannabidiol (CBD)-Predominant Medical Cannabis Preparation) in the Management of Refractory Skin Graft Vs Host Disease (GVHD)

Diagnostic Delay and Characterization of the Clinical Prodrome in AL Amyloidosis: Data from 1,313 US Commercially Insured Patients between 2006-2018

Preliminary Results of Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): GELLC7 Trials from the Spanish Group of CLL (GELLC)

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study

Initial Safety and Efficacy of Dose-Escalating HDACs Inhibitor Chidamide with VRD (Chi-VRD) Treatment for Newly-Diagnosed High-Risk Transplant Eligible Multiple Myeloma Patients

A Prospective Pilot Study of Ixazomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed or Relapsed/Refractory POEMS Syndrome

Upfront Ixazomib Plus Dexamethasone Induce Promptly Hematological Response in Patients with Light-Chain Amyloidosis

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Clinical Features and Outcomes of Unifocal Adult Langerhans Cell Histiocytosis

Neurological Adverse Events Following CAR-T Cell Therapy: A Real-World Analysis of Adult Patients Treated with Axicabtagene Ciloleucel or Tisagenlecleucel

Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only